home / stock / rfm / rfm news

RFM News and Press, RiverNorth Flexible Municipal Income Fund Inc. From 12/18/23

Stock Information
Company Name: RiverNorth Flexible Municipal Income Fund Inc.
Stock Symbol: RFM
Market: NYSE
Website: rivernorth.com/closed-end-funds/rmi
Menu
RFM RFM Quote RFM Short RFM News RFM Articles RFM Message Board
Get RFM Alerts

News, Short Squeeze, Breakout and More Instantly...
RFM - Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO)

Preliminary data demonstrate that SENS-401 has a favorable safety profile when administered continuously for up to 11 weeks in adult patients undergoing cisplatin-based chemotherapy Recruitment is progressing well, with over a third of the required study population enrolled ...
RFM - Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Bernd Schmidt...

RFM - Sensorion Provides Preliminary Documents for the Combined Shareholders' General Meeting of December 20, 2023

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wedne...

RFM - Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce that its management team, includi...
RFM - Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery's Life Sciences Symposium

Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce its partic...

RFM - Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference

Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce its participation, in-person...

RFM - Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023

Regulatory News: Sensorion (FR0012596468 – ALSEN) , a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, Sensorion announces the availability of its 1st H...
RFM - Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023

Sensorion to host a webconference dedicated to shareholders on September 25 th , 2023, in French, at 6am ET (12pm CET) Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel...

RFM - Sensorion Reports 2023 First Half Results

Development milestone achieved for SENS-501 (OTOF-GT) program with the submission of Clinical Trial Applications in the UK and in Europe GJB2-GT advancing towards IND-enabling activities after candidate selection Positive preliminary efficacy results of Proof-of-Concept Ph...

RFM - Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announced that it has submitted ...
Previous 10 Next 10